Examining the incidence of COVID-19 infections
Official title: Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement
Run by Centre Hospitalier Universitaire de Nice · NCT04429594 · Data updated 2026-11-12
This study is trying to see how common COVID-19 infections are and how air pollution affects people's immune responses and health during the reopening phase after lockdowns.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice) |
| Status | Recruiting |
| Started | July 28, 2020 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT04429594 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults who have been exposed to the public since May 11, 2020, and are informed about the study.
✕Probably not a fit
Patients who are under legal protection or unable to participate in clinical studies due to health regulations will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study aims to determine the prevalence and incidence of COVID-19 infections using serological and PCR tests among approximately 1000 subjects during the deconfinement phase. Participants will serve as their own controls, comparing their immune responses and epigenetic markers before and after exposure to air pollutants as economic activities resume. The study will also assess the impact of these pollutants on various health outcomes, including infectious and autoimmune events.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the relationship between air pollution and COVID-19 infection rates, potentially guiding public health policies.
How similar studies have gone: While studies on the impact of air pollution on health are common, this specific approach to linking it with COVID-19 incidence is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any major subject, voluntary, exposed to the public from 11 May 2020 informed of the study by partner institutions (Departmental Council 06), affiliated to a social security scheme, Exclusion Criteria: * Subject protected by law under tutorship or guardianship, or who cannot participate in a clinical study under the terms of Article L. 1121-16 of the French Public Health Code
Where it's running
-
University Nice Hospital
Nice, France Recruiting
Study contacts
- Study coordinator: Barbara SEITZ, MCUPH
- Email: seitz-polski.b@chu-nice.fr
- Phone: 334 92 03 55 02
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating Baricitinib for Long COVID Symptoms
This study is testing if the medication baricitinib can help adults with Long COVID feel better physically and mentally compared to a placebo.
-
In-depth investigation of the immune response to COVID-19
This study looks at the immune responses of hospitalized COVID-19 patients to see what makes some people get sicker than others.
-
Characterizing COVID-19 patients to predict treatment outcomes
This study looks at COVID-19 patients to see if certain factors can help predict how severe their illness will be and how well they might respond to different treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.